Skip to search formSkip to main contentSkip to account menu

MK 1775

Known as: MK-1775, MK1775 
National Institutes of Health

Related topics

Related topics

3 relations
AZD1775

Broader (2)

PyrazolesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel
Wee1 kinase is a crucial negative regulator of Cdk1/cyclin B1 activity and is required for normal entry into and exit from… 
2017
2017
Improving pharmacological targeting of AKT in melanoma.
2017
2017
WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability
[This corrects the article DOI: 10.3892/ol.2017.6584.]. 
2016
2016
Abstract P5-03-06: MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) receptor agonist, induces apoptotic cell death in breast cancer cells
TRAIL receptor agonists are attractive anti-tumor agents because of their capability to induce apoptosis in cancer cells by… 
2015
2015
An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.
5506 Background: Data suggest synthetic lethality when TP53-deficient cells are exposed to genotoxic drugs plus the Wee1… 
2014
2014
Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumors.
2503 Background: Wee1 tyrosine kinase phosphorylates and inactivates Cdk1, causing G2 cell cycle arrest in response to DNA damage… 
2011
2011
Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with…
3068 Background: MK-1775 (MK) is an investigational inhibitor of the Wee1 kinase regulating the G2 checkpoint leading to chemo… 
2011
2011
Preclinical Development MK 1775 , a Selective Wee 1 Inhibitor , Shows Single-Agent Antitumor Activity against Sarcoma Cells
Wee1 is a critical component of the G2–M cell-cycle checkpoint control and mediates cell-cycle arrest by regulating the… 
2010
2010
A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced…
3067 Background: MK-1775 (MK) is an inhibitor of the Wee1 kinase regulating the G2 checkpoint leading to chemo-sensitization in… 
2009
2009
A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid…
3510 Background: MK-1775 is an inhibitor of Wee1, a kinase that phosphorylates CDC2 to inactivate the CDC2/cyclin B complex… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)